CD19 and neoplasm: In contrast to CD19-specific CAR-αβT cells, CD19-directed CAR-γδT cells have shown reactivity against both CD19-positive and negative tumor cells in vitro and in vivo, an effect that was enhanced by ZOL, suggesting that CD19-directed CAR-γδT cells may target leukemic cells also after antigen loss and retain tumor antigen recognition via their γδTCR [100].